18-01992-E

January 17 2018

US Securities & Exchange Commission Office of FOIA and Privacy Act Operations 100 F Street, NE Mail Stop 5100 Washington, DC 20549-5100 JAN 17 2018

Office of FOIA Services

Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit: 10.1 to the form 10-Q filed by AVANT IMMUNOTHERAPEUTICS INC on May 19, 2008

In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

Paul D'Souza Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ

Phone: +44-2074334789 paul.dsouza@clarivate.com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATION PLACE 100 F STREET, NE WASHINGTON, DC 20549-2465

Office of FOIA Services

January 22, 2018

Mr. Paul D'Souza Clarivate Analytics 160 Blackfriars Road London, 1U SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552

Request No. 18-01992-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on January 17, 2018, for Exhibit 10.1 to the Form 10-Q filed by Avant Immunotherapeutics, Inc. on May 19, 2008.

The Commission granted confidential treatment to Exhibit 10.1 to the Form 10-Q under Rule 24b-2 of the Securities and Exchange Act of 1934 through May 19, 2018. Since confidential treatment has not expired, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me at jacksonw@sec.gov or (202) 551-8312. You may also contact me at <u>foiapa@sec.gov</u> or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Jeffery Ovall at (202) 551-7900.

Sincerely,

Warren E. Jackson

FOIA Research Specialist